First human test of OPT101 drug shows no major breakthrough yet
NCT ID NCT04589403
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 32 times
Summary
This early-stage study tested a new drug, OPT101, in 14 healthy volunteers to see if it is safe and how the body processes it. Participants received either the drug or a placebo, and researchers monitored side effects, vital signs, and lab results. Since this is a first-in-human trial, the goal was not to treat any disease but to gather safety information for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IMMUNOe Research
Centennial, Colorado, 80112, United States
Conditions
Explore the condition pages connected to this study.